Zolbetuximab

佐妥昔单抗

Report date: 2025/01/02 16:48:32
First In Class

Base Information

Drug NameZolbetuximab
Drug Alias NameClaudiximabZolbetuximab-CLZBVyloyVYLOY威络益 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPain +[8] 
Global Approved IndicationsStomach NeoplasmsEsophageal Neoplasms
Approved Indications in ChinaStomach NeoplasmsEsophageal Neoplasms
Original Approved Country/TerritoryJapan
Original Approved Date2024/03/26
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGanymed
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma Us IncBaxter Oncology GmbhAstellas Pharma Europe Bv +[6] 
Inactive CompaniesGanymed Pharmaceuticals Gmbh
Active IndicationsGastroesophageal Junction NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[5] 
Inactive IndicationsSolid tumoursPainLymphangioma, Cystic

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG